IQVIA

factnew IQVIA reported FY2025 revenue of $16,310M (+5.9%), of which the Technology & Analytics Solutions (TAS) segment — the data/analytics/commercial-tech business that directly competes with RWD vendors — was $6,626M (+7.6% reported, +6.2% constant currency), with R&D Solutions (the CRO) at $8,896M and Contract Sales & Medical Solutions at $788M.

factnew Effective Jan 1 2026 IQVIA replaced its three-segment structure (TAS / R&DS / CSMS) with two segments — Commercial Solutions and Research & Development Solutions — and Q1 2026 Commercial Solutions revenue (which now absorbs the former TAS data/analytics plus contract-sales businesses) was $1,754M (+11.6% reported, +8.5% cc), further diluting the standalone RWD revenue signal.

factnew IQVIA reaffirmed FY2026 revenue guidance of $17,150M-$17,350M (assuming ~150bps from acquisitions and ~100bps FX), carried net debt of $13,886M at a 3.62x leverage ratio as of Q1 2026, and in early June 2026 priced a €950M senior-notes offering (4.625%, due 2033) to refinance existing debt — i.e. an acquisitive, leveraged compounder, not an organic-only grower.

factnew IQVIA's FY2025 10-K states no single client accounted for 10% or more of total revenues in 2025 or 2024 and that it serves 10,000+ clients in 100+ countries, while the March 2026 IQVIA.ai launch claims 19 of the top 20 pharmaceutical companies are using IQVIA agents — a diversified, near-universal top-pharma footprint with no single-customer dependency.

factnew Per its FY2025 10-K, IQVIA holds more than 1.2 billion comprehensive, longitudinal non-identified patient records and ~68 petabytes of proprietary data covering prescription, promotional, social-media, medical-claims, electronic-medical-record and genomics data, sourced from approximately 150,000 data suppliers, ingesting ~120 billion healthcare records annually and tracking 22M+ healthcare professionals — but that supplier dependency is itself disclosed as a principal risk (license restrictions/refusals).

factnew IQVIA launched IQVIA.ai — a unified agentic-AI platform spanning clinical, commercial and real-world domains, built on NVIDIA Nemotron/NeMo/Dynamo and IQVIA's Healthcare-grade AI — at NVIDIA GTC on March 16 2026, describing it as an 'initial release' with additional agents/capabilities 'expected in Q4' and claiming 19 of the top 20 pharma have begun incorporating IQVIA agents, though no specific customers are named.

factnew The IQVIA-NVIDIA agentic-AI partnership ran on a build-up timeline — announced at JPM/CES in January 2025 (custom foundation models on NVIDIA AI Foundry over IQVIA's then-64PB of data), first 'orchestrator' agents for clinical trials and commercialization demoed at GTC Paris in June 2025, then the unified IQVIA.ai platform in March 2026 — so the deep agent catalog was roadmap through most of 2025 and only productized in 2026.

factnew IQVIA and Veeva ended their 8-year legal dispute (filed 2017; IQVIA alleged trade-secret misuse, Veeva counterclaimed antitrust over data access) in August 2025 — all claims dismissed with prejudice, no damages between the parties (Veeva paying ~$31M to law firms), plus a new partnership giving life-sciences customers access to both firms' software and data, removing a long-standing data-access antitrust overhang.

factnew The FTC sued (July 2023) and won a preliminary injunction (Dec 2023) blocking IQVIA's acquisition of Propel Media/DeepIntent in healthcare programmatic advertising — IQVIA abandoned the deal in January 2024 — with the FTC characterizing IQVIA as 'the world's largest provider of healthcare data' and alleging it could restrict rivals' access to key data inputs, an independent (regulator-sourced) confirmation of both IQVIA's data dominance and a data-gatekeeping reputational vulnerability.

factnew IQVIA actively positions its RWD/RWE for regulatory decision-making — publishing a 'Best Practices for RWD/RWE Used in Regulatory Filings' white paper and case studies of FDA label expansions supported by RWE — but its publicly documented regulatory wins are client-anonymized case studies rather than named, marquee submissions, a softer external track record than Flatiron's named oncology label expansion or Aetion's RCT-DUPLICATE work.

factnew ClinicalTrials.gov lists 50+ active trials with IQVIA as sponsor/collaborator, dominated by interventional CRO work but including a steady stream of Post-Authorisation Safety Studies and real-world/observational studies (e.g. a pan-European exenatide pancreatic-cancer PASS, Tezspire cardiac-events PASS, anifrolumab safety studies), evidencing an active regulatory-pharmacovigilance/RWE study practice on top of the CRO.

factnew Over 800 PubMed papers carry an IQVIA affiliation since Jan 2025, with a large share being RWE studies built on IQVIA's German outpatient/Disease Analyzer EMR database (e.g. Kostev et al. oncology and dermatology RWE), indicating a productive clinical-RWE publication engine that is heavily concentrated in European primary-care EMR rather than US curated oncology/specialty EHR.

factnew IQVIA's open-roles board skews heavily to oncology and clinical-operations (CRO) hiring with scattered RWE/epidemiology roles (e.g. 'Senior Epidemiologist, Inflammation, RWE & Regulatory Strategy') and several AI/LLM-tagged postings, consistent with a CRO-plus-RWE-for-regulators plus AI-platform build-out — though Workday's 2,000-job cap makes absolute counts unreliable.

factnew Federal agencies are recurring paying customers of IQVIA RWD — FDA CBER's Biologics Effectiveness and Safety (BEST) surveillance program ($5.4M FY2024 + $4.4M FY2025), HHS 'IQVIA Pharmacy Data' ($15.8M + $12.1M) and outpatient-Rx/drug-utilization IDIQs (~$19.7M), and DOJ pharmaceutical-prescription data ($7.0M + $4.3M) — validating IQVIA's data for regulatory-grade use, but every award is for prescription/pharmacy/sales/claims data, with no clinical/EHR procurement in the window.

factnew IQVIA reported FY2025 revenue of $16,310M (+5.9%), of which the Technology & Analytics Solutions (TAS) segment — the data/analytics/commercial-tech business that directly competes with RWD vendors — was $6,626M (+7.6% reported, +6.2% constant currency), with R&D Solutions (the CRO) at $8,896M and Contract Sales & Medical Solutions at $788M.

factnew Effective Jan 1 2026 IQVIA replaced its three-segment structure (TAS / R&DS / CSMS) with two segments — Commercial Solutions and Research & Development Solutions — and Q1 2026 Commercial Solutions revenue (which now absorbs the former TAS data/analytics plus contract-sales businesses) was $1,754M (+11.6% reported, +8.5% cc), further diluting the standalone RWD revenue signal.

factnew IQVIA reaffirmed FY2026 revenue guidance of $17,150M-$17,350M (assuming ~150bps from acquisitions and ~100bps FX), carried net debt of $13,886M at a 3.62x leverage ratio as of Q1 2026, and in early June 2026 priced a €950M senior-notes offering (4.625%, due 2033) to refinance existing debt — i.e. an acquisitive, leveraged compounder, not an organic-only grower.

factnew IQVIA's FY2025 10-K states no single client accounted for 10% or more of total revenues in 2025 or 2024 and that it serves 10,000+ clients in 100+ countries, while the March 2026 IQVIA.ai launch claims 19 of the top 20 pharmaceutical companies are using IQVIA agents — a diversified, near-universal top-pharma footprint with no single-customer dependency.

factnew Per its FY2025 10-K, IQVIA holds more than 1.2 billion comprehensive, longitudinal non-identified patient records and ~68 petabytes of proprietary data covering prescription, promotional, social-media, medical-claims, electronic-medical-record and genomics data, sourced from approximately 150,000 data suppliers, ingesting ~120 billion healthcare records annually and tracking 22M+ healthcare professionals — but that supplier dependency is itself disclosed as a principal risk (license restrictions/refusals).

factnew IQVIA launched IQVIA.ai — a unified agentic-AI platform spanning clinical, commercial and real-world domains, built on NVIDIA Nemotron/NeMo/Dynamo and IQVIA's Healthcare-grade AI — at NVIDIA GTC on March 16 2026, describing it as an 'initial release' with additional agents/capabilities 'expected in Q4' and claiming 19 of the top 20 pharma have begun incorporating IQVIA agents, though no specific customers are named.

factnew The IQVIA-NVIDIA agentic-AI partnership ran on a build-up timeline — announced at JPM/CES in January 2025 (custom foundation models on NVIDIA AI Foundry over IQVIA's then-64PB of data), first 'orchestrator' agents for clinical trials and commercialization demoed at GTC Paris in June 2025, then the unified IQVIA.ai platform in March 2026 — so the deep agent catalog was roadmap through most of 2025 and only productized in 2026.

factnew IQVIA and Veeva ended their 8-year legal dispute (filed 2017; IQVIA alleged trade-secret misuse, Veeva counterclaimed antitrust over data access) in August 2025 — all claims dismissed with prejudice, no damages between the parties (Veeva paying ~$31M to law firms), plus a new partnership giving life-sciences customers access to both firms' software and data, removing a long-standing data-access antitrust overhang.

factnew The FTC sued (July 2023) and won a preliminary injunction (Dec 2023) blocking IQVIA's acquisition of Propel Media/DeepIntent in healthcare programmatic advertising — IQVIA abandoned the deal in January 2024 — with the FTC characterizing IQVIA as 'the world's largest provider of healthcare data' and alleging it could restrict rivals' access to key data inputs, an independent (regulator-sourced) confirmation of both IQVIA's data dominance and a data-gatekeeping reputational vulnerability.

factnew IQVIA actively positions its RWD/RWE for regulatory decision-making — publishing a 'Best Practices for RWD/RWE Used in Regulatory Filings' white paper and case studies of FDA label expansions supported by RWE — but its publicly documented regulatory wins are client-anonymized case studies rather than named, marquee submissions, a softer external track record than Flatiron's named oncology label expansion or Aetion's RCT-DUPLICATE work.

factnew ClinicalTrials.gov lists 50+ active trials with IQVIA as sponsor/collaborator, dominated by interventional CRO work but including a steady stream of Post-Authorisation Safety Studies and real-world/observational studies (e.g. a pan-European exenatide pancreatic-cancer PASS, Tezspire cardiac-events PASS, anifrolumab safety studies), evidencing an active regulatory-pharmacovigilance/RWE study practice on top of the CRO.

factnew Over 800 PubMed papers carry an IQVIA affiliation since Jan 2025, with a large share being RWE studies built on IQVIA's German outpatient/Disease Analyzer EMR database (e.g. Kostev et al. oncology and dermatology RWE), indicating a productive clinical-RWE publication engine that is heavily concentrated in European primary-care EMR rather than US curated oncology/specialty EHR.

factnew IQVIA's open-roles board skews heavily to oncology and clinical-operations (CRO) hiring with scattered RWE/epidemiology roles (e.g. 'Senior Epidemiologist, Inflammation, RWE & Regulatory Strategy') and several AI/LLM-tagged postings, consistent with a CRO-plus-RWE-for-regulators plus AI-platform build-out — though Workday's 2,000-job cap makes absolute counts unreliable.

factnew Federal agencies are recurring paying customers of IQVIA RWD — FDA CBER's Biologics Effectiveness and Safety (BEST) surveillance program ($5.4M FY2024 + $4.4M FY2025), HHS 'IQVIA Pharmacy Data' ($15.8M + $12.1M) and outpatient-Rx/drug-utilization IDIQs (~$19.7M), and DOJ pharmaceutical-prescription data ($7.0M + $4.3M) — validating IQVIA's data for regulatory-grade use, but every award is for prescription/pharmacy/sales/claims data, with no clinical/EHR procurement in the window.